Accelerated Cure Project for Multiple Sclerosis and Arab Board for Clinical Research Partner with the Association of Diversity in Clinical Trials
The Association of Diversity in Clinical Trials (AOD) has announced its newest partners, Accelerated Cure Project for Multiple Sclerosis and Arab Board for Clinical Research. This strategic collaboration aims to drive diversity and inclusion within the realm of clinical trials, addressing longstanding disparities in healthcare access.
AOD, an advocate for diversity and equity in clinical research, has forged these partnerships to expand its impact on underrepresented populations. Accelerated Cure Project for Multiple Sclerosis, a nonprofit organization dedicated to advancing multiple sclerosis (MS) research, shares AOD's commitment to equal access to treatments and therapies for all patients, regardless of their background. The Arab Board for Clinical Research, renowned for its advocacy work in the clinical research space, joins forces with AOD to enhance diversity in clinical trials on a global scale.
"Our partnership with the Accelerated Cure Project for Multiple Sclerosis and the Arab Board for Clinical Research is a vital step in addressing clinical trial disparities," stated Jeremy Mitchell, AOD's director of business development in a press release. "Together, we aim to improve healthcare outcomes for all by ensuring trials reflect our diverse communities."
This collaboration fosters knowledge sharing and strategies for diverse community engagement in clinical trials. AOD, Accelerated Cure Project for Multiple Sclerosis, and the Arab Board for Clinical Research unite for a more inclusive healthcare future.
Reference
Accelerated Cure Project for Multiple Sclerosis and Arab Board for Clinical Research Partner with the Association of Diversity in Clinical Trials. (2023, September 28). Cision PR Newswire.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
